Tested Applications
| Positive IHC detected in | human tonsillitis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human lung cancer tissue |
| Positive IF/ICC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:1000-1:4000 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
84192-3-RR targets Ki-67 in IHC, IF/ICC, IF-P, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | antigen identified by monoclonal antibody Ki-67 |
| Calculated Molecular Weight | 359 kDa |
| GenBank Accession Number | NM_002417 |
| Gene Symbol | KI67 |
| Gene ID (NCBI) | 4288 |
| RRID | AB_3743530 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P46013 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
The Ki-67 protein (also known as MKI67) is a cellular marker for proliferation. Ki67 is present during all active phases of the cell cycle (G1, S, G2 and M), but is absent in resting cells (G0). Cellular content of Ki-67 protein markedly increases during cell progression through S phase of the cell cycle. Therefore, the nuclear expression of Ki67 can be evaluated to assess tumor proliferation by immunohistochemistry. It has been demonstrated to be of prognostic value in breast cancer. In head and neck cancer, several studies have reported an association between high proliferative activity and poorer prognosis.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Ki-67 antibody 84192-3-RR | Download protocol |
| IHC protocol for Ki-67 antibody 84192-3-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The Ki-67 Recombinant monoclonal antibody (241499B1), catalog number 84192-3-RR, has a total of 2 citations. These appear in Annals of Hematology and Discover Nano. The cited research spans oncology/hematology (T-cell lymphoblastic lymphoma treatment) and tissue engineering/regenerative medicine (tendon healing via gene delivery).
| Species | Application | Title |
|---|---|---|
Ann Hematol Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma | ||
Discov Nano Spatially distributed bFGF and VEGFA gene delivery to tendon and peritendinous tissues enhances early tendon healing. |
